3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
5
Melanoma
2
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Meningioma
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Leukemia
1
Healthy Participants
1
Endometrial Neoplasms
1
Disease Progression
1
Chondrosarcoma
1
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
1
Interventions
venetoclax
22
Cyclophosphamide
14
Cytarabine
12
Azacitidine
8
fludarabine
7
Daunorubicin
5
ruxolitinib
4
revumenib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Dexamethasone
4
quizartinib
3
pirtobrutinib
3
gamma-Globulins
3
fludarabine phosphate
3
blinatumomab
3
Tacrolimus
3
Rituximab
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Decitabine
3
Ciprofloxacin
3
Blood Specimen Collection
3
zanubrutinib
2
pembrolizumab
2
ibrutinib
2
aldesleukin
2
acalabrutinib
2
Watchful Waiting
2
Mycophenolic Acid
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia
×
capivasertib
×
Clear all
NCT07294677
2026-03-04
CAVALRY
University of Chicago
Phase 1/2
Recruiting
104 enrolled